Machine Learning Model to Predict Pseudoprogression Versus Progression in Glioblastoma Using MRI: A Multi-Institutional Study (KROG 18-07)
Bum‐Sup Jang, Andrew J. Park, Seung Hyuck Jeon et al. · Cancers · 2020
Some patients with glioblastoma show a worsening presentation in imaging after concurrent chemoradiation, even when they receive gross total resection. Previously, we showed the feasibility of a machine learning model to predict pseudoprogression (PsPD) versus progressive disease (PD) in glioblastoma patients. The previous model was based on the dataset from two institutions (termed as the Seoul National University Hospital (SNUH) dataset, N = 78). To test this model in a larger dataset, we collected cases from multiple institutions that raised the problem of PsPD vs. PD diagnosis in clinics (Korean Radiation Oncology Group (KROG) dataset, N = 104). The dataset was composed of brain MR images and clinical information. We tested the previous model in the KROG dataset; however, that model showed limited performance. After hyperparameter optimization, we developed a deep learning model based on the whole dataset (N = 182). The 10-fold cross validation revealed that the micro-average area under the precision-recall curve (AUPRC) was 0.86. The calibration model was constructed to estimate the interpretable probability directly from the model output. After calibration, the final model offers clinical probability in a web-user interface.
Cited by 37 works. doi:10.3390/cancers12092706 Open-access PDF
Authors
- Bum‐Sup Jang
- Seung Hyuck Jeon
- Il Han Kim
- Il Han Kim
- Shin-Hyung Park
- Ju Hye Lee
- Ji Hyun Chang
- Kwan Ho Cho
- Jin Hee Kim
- Leonard Sunwoo
- Seung Hong Choi
- In Ah Kim
References
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- Obtaining calibrated probability estimates from decision trees and naive Bayesian classifiers
- Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
- MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
- A Problem of Dimensionality: A Simple Example
- Obtaining Well Calibrated Probabilities Using Bayesian Binning
- Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
- Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials